Cargando…

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy

Cushing’s disease (CD) causes diabetes mellitus (DM) through different mechanisms in a significant proportion of patients. Glucose metabolism has rarely been assessed with appropriate testing in CD; we aimed to evaluate hormonal response to a mixed meal tolerance test (MMTT) in CD patients and analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barbot, Mattia, Mondin, Alessandro, Regazzo, Daniela, Guarnotta, Valentina, Basso, Daniela, Giordano, Carla, Scaroni, Carla, Ceccato, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105040/ https://www.ncbi.nlm.nih.gov/pubmed/35563608 http://dx.doi.org/10.3390/ijms23095217

Ejemplares similares

Clinical use of pasireotide for Cushing’s disease in adults
por: Ceccato, Filippo, et al.
Publicado: (2015)

Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
por: Mondin, Alessandro, et al.
Publicado: (2022)

Diabetes Mellitus Secondary to Cushing’s Disease
por: Barbot, Mattia, et al.
Publicado: (2018)

The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome
por: Barbot, Mattia, et al.
Publicado: (2019)

The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas
por: Regazzo, Daniela, et al.
Publicado: (2022)

Consideration on TMPRSS2 and the risk of COVID-19 infection in Cushing’s syndrome
por: Barbot, Mattia, et al.
Publicado: (2020)

How to rule out non-neoplastic hypercortisolemia (previously known as pseudo-cushing)
por: Scaroni, Carla, et al.
Publicado: (2022)

Complications and mortality of Cushing’s disease: report on data collected over a 20-year period at a referral centre
por: Mondin, Alessandro, et al.
Publicado: (2023)

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
por: Pivonello, Rosario, et al.
Publicado: (2019)

Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas
por: Voltan, Giacomo, et al.
Publicado: (2023)

Second-Line Tests in the Diagnosis of Adrenocorticotropic Hormone-Dependent Hypercortisolism
por: Pinelli, Silvia, et al.
Publicado: (2021)

Clinical presentation and management of acromegaly in elderly patients
por: Ceccato, Filippo, et al.
Publicado: (2020)

Silent gonadotroph pituitary neuroendocrine tumor in a patient with tuberous sclerosis complex: evaluation of a possible molecular link
por: Regazzo, Daniela, et al.
Publicado: (2018)

Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients
por: Ceccato, Filippo, et al.
Publicado: (2021)

Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia
por: Barbot, Mattia, et al.
Publicado: (2022)

Vitamin D Deficiency in Cushing’s Disease: Before and After Its Supplementation
por: Guarnotta, Valentina, et al.
Publicado: (2022)

Glucocorticoid excess and COVID-19 disease
por: Guarnotta, Valentina, et al.
Publicado: (2020)

Diagnostic Accuracy of CT Texture Analysis in Adrenal Masses: A Systematic Review
por: Crimì, Filippo, et al.
Publicado: (2022)

Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing’s Disease
por: Guarnotta, Valentina, et al.
Publicado: (2020)

Nutritional Intervention in Cushing’s Disease: The Ketogenic Diet’s Effects on Metabolic Comorbidities and Adrenal Steroids
por: Guarnotta, Valentina, et al.
Publicado: (2023)

The Methylation Analysis of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Locus in GH-Secreting Pituitary Adenomas
por: Dalle Nogare, Mattia, et al.
Publicado: (2023)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score
por: Parasiliti-Caprino, Mirko, et al.
Publicado: (2021)

Low-dose short synacthen test with salivary cortisol in patients with suspected central adrenal insufficiency
por: Ceccato, Filippo, et al.
Publicado: (2021)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
por: Ciresi, A., et al.
Publicado: (2018)

Allelic Variants of ARMC5 in Patients With Adrenal Incidentalomas and in Patients With Cushing's Syndrome Associated With Bilateral Adrenal Nodules
por: Mariani, Beatriz Marinho de Paula, et al.
Publicado: (2020)

Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control
por: Ciresi, Alessandro, et al.
Publicado: (2018)

Preoperative treatment with metyrapone in patients with Cushing’s syndrome due to adrenal adenoma: a pilot prospective study
por: Puglisi, Soraya, et al.
Publicado: (2018)

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Pasireotide treatment in Cushing’s disease: A single tertiary center’s experience
por: ŞAHİN, Serdar, et al.
Publicado: (2021)

Effectiveness of low-dose pasireotide in a patient with Cushing’s disease: antiproliferative effect and predictivity of a short pasireotide suppression test
por: Grossrubatscher, Erika, et al.
Publicado: (2015)

Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report
por: Beretta, Federica, et al.
Publicado: (2020)

Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing’s syndrome, acromegaly and neuroendocrine tumours
por: Guarnotta, Valentina, et al.
Publicado: (2023)

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
por: Petersenn, S., et al.
Publicado: (2017)

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations
por: Colao, Annamaria, et al.
Publicado: (2013)

Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
por: Mizuno, Tomoko, et al.
Publicado: (2021)

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study
por: Manetti, Luca, et al.
Publicado: (2019)

Improved salivary cortisol rhythm with dual-release hydrocortisone
por: Ceccato, Filippo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fbbm21o16inglsv2lg8u8oct5v